文献速递心脑血管急症

经皮冠状动脉血管成形术与冠状动脉旁路移植术治疗无保护左主干狭窄的比较(NOBLE):前瞻性、随机、开放标签、非劣效性试验

Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.
PubMed 文献 · Lancet · 2016-10-31
一句话结论无保护左主干病变患者5年MACCE:PCI组29% vs CABG组19%,HR 1.48(95%CI 1.11–1.96),超过非劣效界值,CABG显著更优(p=0.0066)。

NOBLE试验在36个北欧中心纳入1201例无保护左主干冠心病患者(稳定心绞痛、不稳定心绞痛或非ST段抬高型心肌梗死),随机1:1接受PCI或CABG。主要终点为MACCE(全因死亡、非操作性心肌梗死、任何再次血运重建、卒中复合终点)。5年Kaplan-Meier估计MACCE:PCI组29%(121例事件) vs CABG组19%(81例事件),HR 1.48(95%CI 1.11–1.96),超过预设非劣效界值(HR 1.35),CABG显著优于PCI(p=0.0066)。作者认为CABG可能优于PCI用于左主干病变血运重建。

要点

  • 5年MACCE:PCI组29%(121例事件) vs CABG组19%(81例事件),HR 1.48(95%CI 1.11–1.96),超过非劣效界值,CABG显著更优(p=0.0066)。
  • 5年非操作性心肌梗死:PCI组7% vs CABG组2%,HR 2.88(95%CI 1.40–5.90),p=0.0040。
  • 5年任何再次血运重建:PCI组16% vs CABG组10%,HR 1.50(95%CI 1.04–2.17),p=0.032。
  • 5年全因死亡:PCI组12% vs CABG组9%,HR 1.07(95%CI 0.67–1.72),p=0.77,无显著差异。
  • 5年卒中:PCI组5% vs CABG组2%,HR 2.25(95%CI 0.93–5.48),p=0.073,未达统计学显著。

适用人群与场景

  • 纳入:无保护左主干冠状动脉疾病患者,伴稳定心绞痛、不稳定心绞痛或非ST段抬高型心肌梗死。
  • 排除:24小时内ST段抬高型心肌梗死、被评估为CABG或PCI风险过高、预期生存期小于1年。
  • 场景:36个北欧中心的前瞻性随机试验,非急诊/ICU院前场景。

研究设计与关键结果

  • 研究设计:前瞻性、随机、开放标签、非劣效性试验,36个北欧中心,2008年12月9日至2015年1月21日随机1201例(PCI组598例,CABG组603例),意向性治疗分析每组592例。
  • 主要终点MACCE(全因死亡、非操作性心肌梗死、任何再次血运重建、卒中复合终点)5年Kaplan-Meier估计:PCI组29%(121例事件) vs CABG组19%(81例事件),HR 1.48(95%CI 1.11–1.96),超过非劣效界值HR 1.35,CABG显著优于PCI(p=0.0066)。
  • 符合方案分析:PCI组28% vs CABG组19%,HR 1.55(95%CI 1.18–2.04),p=0.0015。
  • 5年全因死亡:PCI组12% vs CABG组9%,HR 1.07(95%CI 0.67–1.72),p=0.77。
  • 5年非操作性心肌梗死:PCI组7% vs CABG组2%,HR 2.88(95%CI 1.40–5.90),p=0.0040。
  • 5年任何再次血运重建:PCI组16% vs CABG组10%,HR 1.50(95%CI 1.04–2.17),p=0.032。
  • 5年卒中:PCI组5% vs CABG组2%,HR 2.25(95%CI 0.93–5.48),p=0.073。

证据类型、等级与局限

  • 证据类型:前瞻性、随机、开放标签、非劣效性试验(NOBLE),注册号NCT01496651。
  • 作者结论:本研究结果提示CABG可能优于PCI用于左主干冠状动脉疾病治疗。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于无保护左主干冠心病伴稳定心绞痛、不稳定心绞痛或非ST段抬高型心肌梗死患者,NOBLE试验5年MACCE结果显示CABG组低于PCI组(19% vs 29%,HR 1.48,95%CI 1.11–1.96),未达到非劣效性。
  • 作者认为CABG可能优于PCI用于左主干病变血运重建。

指南或共识出处

  • NOBLE试验,发表于Lancet,ClinicalTrials.gov注册号NCT01496651。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Coronary artery bypass grafting (CABG) is the standard treatment for revascularisation in patients with left main coronary artery disease, but use of percutaneous coronary intervention (PCI) for this indication is increasing. We aimed to compare PCI and CABG for treatment of left main coronary artery disease.

METHODS: In this prospective, randomised, open-label, non-inferiority trial, patients with left main coronary artery disease were enrolled in 36 centres in northern Europe and randomised 1:1 to treatment with PCI or CABG. Eligible patients had stable angina pectoris, unstable angina pectoris, or non-ST-elevation myocardial infarction. Exclusion criteria were ST-elevation myocardial infarction within 24 h, being considered too high risk for CABG or PCI, or expected survival of less than 1 year. The primary endpoint was major adverse cardiac or cerebrovascular events (MACCE), a composite of all-cause mortality, non-procedural myocardial infarction, any repeat coronary revascularisation, and stroke. Non-inferiority of PCI to CABG required the lower end of the 95% CI not to exceed a hazard ratio (HR) of 1·35 after up to 5 years of follow-up. The intention-to-treat principle was used in the analysis if not specified otherwise. This trial is registered with ClinicalTrials.gov identifier, number NCT01496651.

FINDINGS: Between Dec 9, 2008, and Jan 21, 2015, 1201 patients were randomly assigned, 598 to PCI and 603 to CABG, and 592 in each group entered analysis by intention to treat. Kaplan-Meier 5 year estimates of MACCE were 29% for PCI (121 events) and 19% for CABG (81 events), HR 1·48 (95% CI 1·11-1·96), exceeding the limit for non-inferiority, and CABG was significantly better than PCI (p=0·0066). As-treated estimates were 28% versus 19% (1·55, 1·18-2·04, p=0·0015). Comparing PCI with CABG, 5 year estimates were 12% versus 9% (1·07, 0·67-1·72, p=0·77) for all-cause mortality, 7% versus 2% (2·88, 1·40-5·90, p=0·0040) for non-procedural myocardial infarction, 16% versus 10% (1·50, 1·04-2·17, p=0·032) for any revascularisation, and 5% versus 2% (2·25, 0·93-5·48, p=0·073) for stroke.

INTERPRETATION: The findings of this study suggest that CABG might be better than PCI for treatment of left main stem coronary artery disease.

FUNDING: Biosensors, Aarhus University Hospital, and participating sites.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Mäkikallio T, Holm NR, Lindsay M, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet. 2016. PMID: 27810312. doi:10.1016/S0140-6736(16)32052-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。